India’s Drug Controller General VG Somani on Tuesday informed that Luv Agarwal, Joint Secretary in the Ministry of Health, said that India’s Drug Controller General VG Somani approved the use of Novel Drug Remdesivir of Gilead Sciences Inc. to be used in treating Covid-19 patients.
Aggarwal said in a press conference, “DCGI has allowed an emergency use for Remdesivir. This is based on the evidence the company provided to support its use fighting against Coronavirus.” Aggarwal said further details on the protocol for drug use would be provided by the government at an appropriate time.
In India, Gilead has granted a voluntary license to Cipla, Jubilant Life Sciences, Hetero Drugs, and Mylan until an alternative medicine is found under a royalty-free arrangement or the removal of the designation of World Health Insurance.
Gilead’s Remdesivir was previously under trial for Ebola, but the drug could not pass clinical trials. However, the Covid-19 epidemic has given the drug a new life, which experts have described as complicated to manufacture.
Gilead Sciences Inc. said on Monday that its phase 3 clinical trial in hospitalized patients with moderate COVID-19 pneumonia showed that the five-day treatment course of remdeisivir had been more efficient clinically than standard care alone.
Follow us on:
However, the corona’s firepower has decreased in the country. Now more than 90 percent of patients are coming out with mild symptoms. This is to say of Dr. Randeep Guleria, AIIMS Director. According to him, the virus that was initially had a serious symptom.
People affected by that were kept in isolation so it did not spread much. The AIIMS director said in a special conversation with ‘Hindustan’ that more than 80% of cases in 12 to 13 cities are there. If we control the hotspot, then the peak will come down in two to three weeks. If the cases are less and it takes more time to double, then the peak will come down soon.